Company Project Advancement - The company is actively promoting the market launch and sales of calcium silicate bio-ceramic oral bone repair materials, planning to adopt a differentiated marketing strategy based on product innovation advantages [1] - The meningeal series products have won bids in 24 provinces for volume procurement projects, with the Beijing-Tianjin-Hebei "3+N" alliance procurement project set to start in December 2025, and the company is progressing with related preparations as planned [1] Product Development Progress - The uterine cavity repair membrane is set to enter the registration phase in early January 2026, having received the registration acceptance notice [2] - The breast patch is expected to complete clinical trial summaries by November 2025, and preparations for registration are currently underway [2] Company Business Status - In 2026, the company plans to accelerate the market promotion and terminal volume of active biological bone to enhance revenue contribution [3] - Several products have export potential, and the company is evaluating market access requirements and feasibility in different countries and regions, conducting preliminary preparation work [3]

Core Viewpoint - Zhenghai Biological has initiated the registration phase for its intrauterine repair membrane product, having received the registration acceptance notice, with further evaluation and approval steps to follow [1] Group 1 - The intrauterine repair membrane product was officially pushed into the registration phase in early January 2023 [1] - The company has completed the clinical trial summary for its breast patch project by November 2025 and is currently preparing for product registration [1] - The company will fulfill its information disclosure obligations in accordance with regulatory requirements regarding the progress of product development [1]

Group 1: Revenue and Market Trends - The company's oral repair membrane revenue has slightly declined in the past two years due to product price fluctuations and increased competition in the private dental market [4] - The demand for dental implants is slowing down, but the company aims to strengthen its market position through precise marketing strategies and collaboration with leading end-users [4] - The company remains optimistic about the growth potential in the dental implant market, as there is still a significant gap in penetration rates compared to developed countries [5] Group 2: Product Development and Market Position - The company’s calcium silicate bio-ceramic oral bone repair material is designed for use with barrier membranes and is suitable for alveolar bone defect repair [4] - The company has prepared for product launch by ensuring sufficient production capacity and developing a differentiated marketing strategy based on innovative material components [4] - The uterine repair membrane is currently in the registration phase, while the breast patch project has completed clinical trials and is preparing for registration [6] Group 3: Future Plans and Financing - The company will assess the necessity of financing based on future strategic needs and overall capital structure [6] - The company is committed to maintaining transparent communication with investors and adhering to information disclosure regulations [6]

Core Viewpoint - Zhenghai Biological (300653) emphasizes the high R&D investment and long time span required for the development and commercialization of medical devices, particularly Class III medical devices [1] Group 1: Product Development - The company is advancing the product registration of calcium silicate biological ceramic bone repair materials and intrauterine repair membranes [1] - Clinical trial summary work is underway for breast patches [1] Group 2: Research and Development Strategy - The company is actively exploring and researching in fields such as genetic engineering and synthetic biology to ensure a robust R&D pipeline [1] - This strategy aims to support the company's long-term development [1]

Core Viewpoint - Zhenghai Biological (300653) announced on October 27 that the development of its intrauterine repair membrane and breast patch products is progressing smoothly, with plans for product registration and sales strategy based on market conditions [1] Group 1: Product Development - The intrauterine repair membrane product has completed clinical trials and is currently advancing through the product registration process [1] - The breast patch product is in the clinical summary stage [1] Group 2: Sales Strategy - The company will consider the development progress of both products and the market conditions of the corresponding application departments to formulate a sales plan [1] - The aim is to maximize the value of these products in driving revenue growth [1]

Group 1: Company Performance Overview - In the first three quarters of 2025, the company achieved operating revenue of 276 million yuan, a decrease of 5.36% compared to the same period last year [4] - The net profit attributable to shareholders was 67.4 million yuan, down 46.10% year-on-year [4] - The net profit after deducting non-recurring gains and losses reached 59.2 million yuan, a decrease of 45.34% compared to the previous year [4] Group 2: Product Development and Market Strategy - The active biological bone product is a key driver for revenue growth, with ongoing efforts to enhance market coverage and penetration in leading hospitals [5] - The company is actively developing new products, including calcium silicate bio-ceramic bone repair materials, which are in the registration phase [4] - The oral implant market is currently facing weak demand, particularly in the private sector, but the company maintains a stable market position for its oral repair membrane products [5] Group 3: Sales and Marketing Initiatives - The company has established an independent sales team focused on the active biological bone product to enhance market promotion capabilities [7] - Flexible sales policies and long-term relationships with distributors are being pursued to boost product market promotion and hospital admissions [5] - Plans for overseas market expansion are underway, with certain products identified as having export potential [7] Group 4: Research and Development Progress - The company is collaborating with Jiangsu Jicui Future Food Technology Research Institute on the development of recombinant bioactive protein products, with steady progress reported [7] - The research and development of the uterine repair membrane and breast patch products are ongoing, with clinical trials completed for the former [6] Group 5: Investor Relations and Future Outlook - The company has consistently maintained performance dividends since its listing and plans to continue investor return strategies based on overall performance [6] - Employee incentive plans are being developed in accordance with relevant regulations to enhance motivation and performance [6]

Summary of Zhenghai Biological Conference Call Company Overview - **Company**: Zhenghai Biological - **Industry**: Biopharmaceuticals, specifically focusing on bone repair materials and dental products Key Points and Arguments Financial Performance - **Net Profit Decline**: Net profit decreased by 45.34% year-on-year, primarily due to tax policy adjustments (VAT increased from 3% to 13%) and intensified market competition, particularly in the meninges product segment and oral implant sector [2][4][5] - **Revenue Trends**: For the first three quarters of 2025, total revenue was 276 million yuan, a decrease of 5.36% year-on-year. In Q3 alone, revenue was 87.87 million yuan, down approximately 5% year-on-year [3][4] - **Gross Margin**: The overall gross margin was around 85%, showing a recovery compared to the first half of the year due to changes in product mix [3] Product Performance - **Active Biological Bone Products**: Currently in 196 hospitals, with expectations for significant revenue growth due to the inclusion of BMP-2, which enhances bone induction. The company aims to increase market share by expanding hospital admissions and improving penetration in benchmark hospitals [2][6][11] - **Stem Cell Project**: In the process of technology validation, this project is crucial for addressing clinical tissue repair and regeneration issues, indicating strategic importance [7] - **Oral Membrane Products**: The second-generation oral repair membrane is in the early promotion stage, contributing minimally to revenue. The company is focusing on applications in soft tissue defects and avoiding price wars [2][8][10] Market Dynamics - **Market Competition**: The oral implant market is facing challenges due to price governance and a sluggish consumer market, leading to a decline in private institution implant volumes. Some patients are opting for repair treatments instead of implants, impacting the growth of bone powder and membranes [2][13] - **Price Pressure**: The company is experiencing price declines across its products, although it maintains a stable gross margin. Sales and management expenses have increased, putting pressure on net profits [5][16] Regulatory and Development Updates - **Regulatory Approvals**: The company is tracking the procurement policies for artificial bone repair materials and is preparing for the registration of new products like the calcium silicate bone powder, expected to receive certification by the end of this year or early next year [4][20] - **Future Product Launches**: The company anticipates launching the intrauterine repair membrane in 2026 and the breast patch in 2027, with detailed market strategies to be developed closer to launch dates [17] Strategic Outlook - **Acquisition Plans**: The company is open to acquisitions to expand its business pipeline and explore new growth opportunities [29] - **International Expansion**: Zhenghai Biological is exploring overseas business opportunities and has begun preparations for international certifications [28] - **Employee Incentives**: The company has completed share buybacks for employee incentives and plans to implement stock incentive schemes based on future performance [30] Future Market Perspective - **Confidence in Growth**: The company remains optimistic about future development, focusing on core business growth, new product launches, and cost control to achieve good performance returns [31]

Core Insights - The company shows signs of short-term recovery with revenue and profit growth, but faces long-term stagnation in core business growth and structural challenges [1] - The core business, particularly the hard dura mater patch segment, is under pressure from multiple factors including price system disruptions due to centralized procurement policies and competition from domestic products [1][6] - The company has not successfully developed a second growth curve, with ongoing reductions in R&D investment and low efficiency in technology transfer [1][8] Financial Performance - In the first half of 2025, the company reported revenue of 201 million yuan, a slight increase of 5.89% year-on-year, and a net profit of 20.4 million yuan, with a growth rate of only 1.27% [2] - Over the past five years, revenue has declined from 437 million yuan in 2020 to 377 million yuan in 2024, a cumulative decrease of 13.7% [2] - The first half of 2025 revenue represents only 53.3% of the total revenue for 2024, indicating potential challenges in achieving a full-year revenue of 400 million yuan [2] Core Business Challenges - The hard dura mater patch, which is the company's main product, generated 74.44 million yuan in the first half of 2025, accounting for 50.6% of the medical device segment's revenue [4] - Revenue growth for the biological dura mater patch was only 1.35%, and it experienced a decline of 14.7% in 2024 [4][6] - The average revenue growth rate for the biological dura mater patch from 2022 to 2024 was only 1.2%, significantly lower than the double-digit growth seen from 2019 to 2021 [4] Competitive Pressures - Centralized procurement policies have led to a price drop of approximately 30% for the hard dura mater patch, which has not been offset by volume increases [6] - Domestic competitors are rapidly advancing in technology, further intensifying market competition [6][10] - The company has not introduced significant upgrades to its hard dura mater patch products in over a decade, leading to stagnation in growth [7] R&D and Innovation - R&D spending has decreased from 57.9 million yuan in 2022 to 42.31 million yuan in 2024, with the proportion of R&D expenses to revenue falling from 15.4% to 9.6% [8] - The company has maintained a stable number of R&D personnel but has not achieved any capitalized R&D projects, indicating a lack of progress in converting R&D into revenue [8] - The company is exploring advanced fields like artificial liver and CAR-T but lacks synergy with its core dura mater patch business [8] Dependency on Core Product - The company is overly reliant on the hard dura mater patch, with other products in the medical device segment unable to significantly contribute to revenue [9] - Other medical device products, such as the chest repair membrane, have shown declining revenues, and the pharmaceutical and cell technology segments have also underperformed [9][10] - The hard dura mater patch holds a market share of 30%, but faces significant pricing pressure from centralized procurement [10]

Core Viewpoint - Zhenghai Biological's performance in the first half of 2025 shows a significant decline in revenue and net profit, primarily due to the contrasting performance of its core products, with the membrane series growing while the oral repair membrane business suffers a decline [1][2][3]. Financial Performance - The company reported a revenue of 187 million yuan, a year-on-year decrease of 5.14% [1]. - The net profit attributable to shareholders was 46.49 million yuan, down 45.97%, marking the largest decline since its listing [1]. - The gross profit margin decreased by 2.81 percentage points to 83.92%, and the net profit margin fell from 43.45% to 24.75% [3]. Product Performance - The membrane series products achieved sales of 80.27 million yuan, a year-on-year increase of 5.88%, benefiting from continued success in centralized procurement [1][2]. - In contrast, the oral repair membrane's revenue was 77.12 million yuan, down 19.38%, with a gross margin decline of 1.63 percentage points to 85.98% [2][3]. - The company attributes the decline in the oral repair membrane segment to intense competition in the private market and a lack of demand in the dental implant market [2]. Marketing and Sales Strategy - Sales expenses increased by 38.87% to 71.18 million yuan, primarily for market promotion and competitive marketing strategies [1][3]. - Despite the increase in marketing expenses, the sales expense ratio rose from 25.88% to 37.90%, indicating that higher spending did not translate into improved market share [3]. New Product Development - The company is focusing on new products like active biological bone, which has started sales in 2023, but specific revenue figures have not been disclosed [5]. - Future products, including calcium silicate biological ceramic bone repair materials and uterine cavity repair membranes, are in various stages of development and are expected to contribute to revenue in the next 2-3 years [5][6]. - The success of new products will depend on their ability to gain market share amidst intense competition [6].

Core Viewpoint - The company experienced a decline in revenue and net profit in the first half of 2025, attributed to changes in tax regulations and a slow recovery in consumer medical demand, particularly in oral repair membranes and increased competition in the market [1][2][3] Group 1: Financial Performance - In 1H25, the company reported revenue of 1.88 billion yuan, a decrease of 5.1% year-on-year, with net profit attributable to shareholders at 0.46 billion yuan, down 45.6% [1] - The second quarter of 2025 saw revenue of 0.90 billion yuan, a decline of 16.6% year-on-year, and net profit of 0.20 billion yuan, down 56.5% [1] - The company anticipates a gradual improvement in performance as consumer medical demand recovers and surgical volumes increase [1] Group 2: Product Performance - Revenue from oral repair membranes in 1H25 was 0.77 billion yuan, a year-on-year decrease of 19.4%, with a gross margin of 85.98%, down 1.63 percentage points [1] - The company’s meningeal products achieved stable growth, with revenue of 0.80 billion yuan in 1H25, reflecting a 5.9% year-on-year increase and a gross margin of 88.84%, down 3.04 percentage points [2] - New product developments include the approval of oral repair membranes for additional indications and ongoing clinical trials for breast patches and uterine repair membranes [2] Group 3: Cost and Expense Management - In 1H25, the sales expense ratio increased to 37.89%, reflecting a year-on-year rise of 12.01 percentage points, while the overall gross margin decreased to 83.92%, down 2.81 percentage points [2] - The company is increasing investment in sales expenses, which is contributing to the higher sales expense ratio [2] Group 4: Future Outlook - The company has adjusted its revenue growth and gross margin expectations for oral repair membranes and bone repair materials downward, while increasing the sales expense ratio forecast [3] - Projected net profits for 2025-2027 are 1.17 billion yuan, 1.30 billion yuan, and 1.44 billion yuan, respectively, with a corresponding EPS of 0.65, 0.72, and 0.80 yuan [3] - The target price for 2025 is set at 25.38 yuan, based on a PE ratio of 39x [3]